METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer

• Published in: Biochimica et biophysica acta. General subjects Vol. 1868; no. 3; p. 130542
• Main Authors: Zhou, Shaocheng, Sheng, Lijuan, Zhang, Lin, Zhang, Jianan, Wang, Lei
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2024
• Subjects: Adenine - analogs & derivatives; Doxorubicin - pharmacology; Humans; Methyltransferases - genetics; RNA, Messenger; Triple Negative Breast Neoplasms; m6A modification; Chemoresistance; METTL3; Breast cancer; HYOU1; IGF2BP3; Doxorubicin

Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP...